Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 3Terminated 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3CNS 1

Conditions

Neuroendocrine Tumors 3Neuroblastoma 1Meningioma 1Medulloblastoma 1

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 330Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 281Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × OTHER × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

NCT03197012 2020-07-07

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

University of California, San Francisco

Phase EARLY_PHASE1 Completed
10 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04296149 2020-03-05

RADIONET

European Institute of Oncology

Phase 2 Completed
5 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡